Welcome to our dedicated page for PRECIGEN SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. reported open-market sales of 200,000 shares of Common Stock under a 10b5-1 trading plan. On June 29, he sold 28,571 shares at a weighted average price of $5.78 per share, followed by 171,429 shares on July 1 at a weighted average price of $5.53 per share. After these transactions, he directly holds 354,535 Common Stock shares.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah exercised stock options to acquire 42,924 shares of common stock at $2.33 per share, then sold the same 42,924 shares at $5.85 per share in an open-market transaction. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. After these transactions, Shah directly holds 497,751 shares of Precigen common stock and retains options covering 157,076 shares.
PRECIGEN, INC. President and CEO Helen Sabzevari reported an exercise-and-sale transaction in company stock. On June 29, 2026, she exercised stock options to acquire 346,836 shares of common stock at $2.33 per share, then sold the same number of shares in open-market transactions at a weighted average price of $5.89 per share.
The sale was carried out under a pre-established Rule 10b5-1 trading plan and involved multiple trades between $5.75 and $6.04. After these transactions, she directly owns 3,768,872 shares of common stock and holds 500,164 stock options, so the sale represents a relatively small portion of her overall equity position.
PGEN Rule 144 notice lists a proposed resale of 28,571 shares of Common Stock by Harry Thomasian Jr., with a reported aggregate sale value of $165,196.70 and a trade date of 06/29/2026. The filing also records multiple Restricted Stock Vesting events with dated share amounts (for example, 68,324 shares vested on 04/05/2024 and 21,625 shares on 08/28/2024). Brokerage information lists Fidelity Brokerage Services LLC at the address shown.
Precigen, Inc. reported results of its 2026 Annual Meeting. Stockholders approved an amendment to the 2023 Omnibus Incentive Plan that increases the shares of common stock available for equity awards by 7 million, following prior approval by the Board, subject to stockholder approval.
Stockholders also elected nine directors for one-year terms, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved a non-binding advisory vote on executive compensation. Each management proposal received substantial support based on the reported vote totals.
PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. reported an open-market sale of 41,884 shares of common stock at $4.36 per share. According to the footnote, this sale was a sell-to-cover transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on May 23, 2026. Following the transaction, he directly holds 554,535 shares of Precigen common stock.
PRECIGEN, INC. Chief Commercial Officer Phil Tennant reported a tax-related share sale. On May 28, 2026, he sold 30,272 shares of common stock at $4.36 per share in a sell-to-cover transaction tied to tax withholding on restricted stock units that vested on May 23, 2026. Following this transaction, he directly holds 139,369 common shares, and the filing shows no remaining derivative positions.